HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TOI

The Oncology Institute, Inc. (NASDAQ)

Healthcare — Medical Care Facilities

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Strong Buy 1.3 / 5 4 analysts
$5.29
$-0.14 (-2.58%)
Target: $7.75 (46.5%)
Sign in to add TOI to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$552.91M
P/E Ratio (TTM)-
Forward P/E-34.56
EPS (TTM)$-0.35
Dividend Yield-
Profit Margin-7.97%
Revenue Growth41.20%
ROE-
Debt/Equity-
Recommendation Strong Buy 1.3
Analyst Target$7.75
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)60.4
Beta0.41
SMA 20-
SMA 40-
52-Week High$5.82
52-Week Low$2.32
50-Day Avg$4.47
200-Day Avg$3.65
Avg Volume$1.89M
Volume$1.58M

Performance Analysis

BULLISH

TOI shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 85% of its 52-week range.
+ RSI at 60.4 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 41.2% year-over-year.
- Operating at a loss with -8.0% margin.
+ Wall Street consensus is "Strong Buy" from 4 analysts.
+ Average analyst target of $7.75 implies 46.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:34 UTC

Back to Screener Export Report